RHYTHM PHARMACEUTICALS, INC. (RYTM) — SEC Financial Statements & Analysis

RHYTHM PHARMACEUTICALS, INC. (RYTM) is a pharmaceutical preparations company, incorporated in DE. RHYTHM PHARMACEUTICALS, INC. trades on Nasdaq as: RYTM. RHYTHM PHARMACEUTICALS, INC. (RYTM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, RHYTHM PHARMACEUTICALS, INC. carries a market cap of $7.62B, a P/E ratio of -35.77x, a P/B ratio of 73.95x, a P/S ratio of 31.74x, an enterprise value of $7.66B, and an EV/EBITDA multiple of -38.16x. On profitability, it posts a gross margin of 89.00%, an operating margin of -83.62%, a net margin of -88.74%, a Return on Equity (ROE) of -467.51%, a Return on Assets (ROA) of -52.57%, and a Return on Invested Capital (ROIC) of -352.93%. Per share, it reports EPS of $-3.10, diluted EPS of $-3.10, free cash flow per share of $-2.12, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 53.51% year-over-year, net income growth of 17.10% year-over-year, and EPS growth of 8.73% year-over-year. On the balance sheet, it maintains a current ratio of 3.45x, a quick ratio of 3.00x, working capital of $302.98M, a debt-to-equity ratio of 2.14x, a debt ratio of 0.5, an interest coverage ratio of -10.86x, free cash flow of $-145.35M (TTM), and net debt of $40.49M. Figures sourced from SEC EDGAR.

Market Cap

$7.62B

P/E TTM

-35.77x

EPS TTM

$-3.10

P/B TTM

73.95x

ROE TTM

-467.51%

ROA TTM

-52.57%

Debt To Equity

2.14x

Free Cash Flow TTM

$-145.35M

Net Revenue TTM Growth 1Y

53.51%

Data as of 2026-06-30 · Source: SEC EDGAR